This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael W. Konstan, University Hospitals Cleveland Medical Center
ClinicalTrials.gov Identifier:
NCT00531882
First received: September 18, 2007
Last updated: June 29, 2017
Last verified: June 2017
September 18, 2007
June 29, 2017
September 2007
February 2009   (Final data collection date for primary outcome measure)
Neutrophil Delivery to the Oral Mucosa Using a Non-invasive Mouthwash Technique [ Time Frame: 3X Before treatment (Days 1,2,3) 3X During treatment (Days 8,9,10) ]
Oral mucosal polymorphonuclear leukocytes (PMN) are obtained and assessed using a modification of the mouthwash method of (Wright et.al. Blood 1986;67:1023-30). For each subject, PMN counts are assessed on days 1, 2, 3 [Baseline (B)]; days 8, 9, 10 [Treatment (T)]; and days 11, 13, 15 [Recovery (R)]. The PMN counts for each subject are averaged for each study time period (B, T or R). Within each study arm (Pioglitazone, Simvastatin and Ibuprofen), mean PMN counts are calculated for time periods B and T. The mean baseline (B) PMN counts are compared to the mean treatment (T) PMN counts for each study arm, with the results expressed as the percent change in PMN counts. Paired T-tests between baseline and treatment PMN counts are used to analyze for significance. The recovery period is used to verify that the PMN counts return to baseline following the treatment period. Data from the recovery period is not shown.
Neutrophil delivery to the oral mucosa using a noninvasive mouth wash technique [ Time Frame: 3x before treatment, 3x during treatment and 3x post treatment ]
Complete list of historical versions of study NCT00531882 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
A Pilot Study Evaluating the Effect of Pioglitazone, Simvastatin, and Ibuprofen on Neutrophil Migration in Vivo in Healthy Subjects

Inflammation clearly contributes to the progression of the cystic fibrosis (CF) lung disease, and administration of the anti-inflammatory agent high-dose ibuprofen retards the rate of decline of pulmonary function. However, utilization of this valuable drug has been suboptimal because of its rare, but dramatic, adverse effects. Therefore, alternative anti-inflammatory agents are urgently needed. One strategy for identifying new anti-inflammatory agents is to determine the mechanism by which the only proven anti-inflammatory agent for the CF lung disease, high-dose ibuprofen, exerts its effect. If this were known, then other drugs that act by a similar mechanism become candidates for treating the CF inflammatory disease. The investigators have shown, in our preliminary studies, that high dose ibuprofen limits the delivery of neutrophils to an inflamed mucosal surface, the gingival crevices. The investigators plan to test pioglitazone and simvastatin, (ibuprofen (positive control)) to determine their anti inflammatory affects on neutrophil migration to the oral mucosa.

The hypothesis to be tested is that pioglitazone, and/or simvastatin will reduce neutrophils in the oral mucosa after 10 days of therapy in mouthwashes of healthy volunteers. Ibuprofen will be used as a positive control.

This study will provide pilot data from healthy volunteers to support an FDA Grant to be submitted at a future date.

The entire study period for each subject will be 15 days, and consist of 3 periods defined as: Baseline (Day 1,2,3), Treatment (Day 3-10), and Recovery (Day 13-15). Healthy volunteers will be screened on Day 1 (and assessed for eligibility); Eligible subjects will be divided into 3 drug treatment groups pioglitazone, simvastatin and ibuprofen the positive control. The two treatment groups will consist of 4 healthy volunteers who meet the inclusion criteria. There will be 2 healthy volunteers in the positive control group. Group 1 will receive pioglitazone 30 mg once daily, Group 2 will receive simvastatin 40 mg daily and Group 3 the positive control will receive ibuprofen (15-23 mg/kg twice daily, maximum 3200 mg/day) during the Treatment period and serve as the positive control group. This dose is 25% of that prescribed to CF patients. As healthy volunteers are recruited, the first will be assigned to Group 1, the second to Group 2, and so on. After the third subject has been assigned to Group 3, this pattern of assignment will be repeated with subjects 4, 5 and 6, The following 4 healthy volunteers will be assigned to group 1 and 2 (7, 8, 9, 10).
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description:
No person associated with the study was masked
Primary Purpose: Other
Cystic Fibrosis
  • Drug: Pioglitazone
    30 mg once a day
    Other Name: ACTOS
  • Drug: Simvastatin
    40 mg once a day
    Other Name: Zocor
  • Drug: Ibuprofen
    Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
    Other Name: Motrin
  • Experimental: 1-pioglitazone
    Pioglitazone
    Intervention: Drug: Pioglitazone
  • Experimental: 2-simvasatin
    Simvastatin
    Intervention: Drug: Simvastatin
  • Active Comparator: 3-Ibuprofen 1000-1600 mg/day
    Ibuprofen 1000-16-- mg/day, maximum 3200 mg/day
    Intervention: Drug: Ibuprofen
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
February 2009
February 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • ≥ 18 < 50 years of age
  • Healthy volunteers must be in general good health as determined by a medical history.
  • Ability to understand and sign the informed consent form
  • Ability to adhere to the protocol.
  • Willing to use an acceptable form of birth control

Exclusion Criteria:

  • History of diabetes requiring insulin
  • The use of NSAIDS (ibuprofen) or corticosteroids including inhaled steroids. Nasal steroids are acceptable.
  • The use of statin lowering medications
  • Active gingival disease (Active tooth or gum disease)
  • Any chronic inflammatory condition that immuno compromises the volunteer as determined by medical history.
  • Pregnant or planning to become pregnant
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00531882
Pilot Healthy Volunteers
No
Not Provided
Plan to Share IPD: No
Michael W. Konstan, University Hospitals Cleveland Medical Center
University Hospitals Cleveland Medical Center
Not Provided
Principal Investigator: Michael W Konstan, MD University Hospitals Cleveland Medical Center
University Hospitals Cleveland Medical Center
June 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP